{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T23:43:51Z","timestamp":1793749431921,"version":"4.6.1"},"reference-count":18,"publisher":"American Medical Association (AMA)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Oncol"],"published-print":{"date-parts":[[2026,8,1]]},"abstract":"\n Importance<\/jats:title>\n \n Approximately 70% of patients with breast cancer (BC) have hormone receptor\u2013positive, human epidermal growth factor receptor 2 (\n ERBB2<\/jats:italic>\n ; formerly\n HER2<\/jats:italic>\n )\u2013negative disease.\n <\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n \n To evaluate the efficacy and safety of fovinaciclib plus an aromatase inhibitor as first-line treatment for hormone receptor\u2013positive,\n ERBB2<\/jats:italic>\n -negative advanced BC.\n <\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n \n This double-blind, phase 3 randomized clinical trial enrolled patients from March 2, 2022, to June 28, 2023, from 63 centers in China. Eligible patients were adult women with hormone receptor\u2013positive,\n ERBB2<\/jats:italic>\n -negative advanced BC and no history of systemic therapy for advanced disease. The data cutoff date was June 25, 2024. Data were analyzed from September to October 2024.\n <\/jats:p>\n <\/jats:sec>\n \n Intervention<\/jats:title>\n Patients were randomized (1:1) to receive fovinaciclib, 200 mg (orally once daily on days 1 to 21), or placebo plus letrozole, 2.5 mg, or anastrozole, 1 mg (orally once daily on days 1 to 28), in 28-day cycles. Premenopausal or perimenopausal patients also received goserelin, 3.6 mg (subcutaneously on day 1).<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n The primary end point was progression-free survival (PFS) per blinded independent central review (BICR). Secondary end points included other efficacy end points and safety. Exploratory end points included overall survival (OS) and quality of life.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Of 417 randomized female patients, the median (range) age was 57.0 (32-84) years. A total of 208 were randomized to the fovinaciclib arm and 209 to the placebo arm. At prespecified interim analysis (median [range] follow-up, 16.6 [0.3-27.8] months), a significantly prolonged median PFS was observed with fovinaciclib compared with placebo (not reached vs 20.2 months [95% CI, 16.4 months to not evaluable]; hazard ratio, 0.55; 95% CI, 0.38-0.77; 1-sided\n P<\/jats:italic>\n \u2009&amp;lt;\u2009.001) per BICR assessments. Consistent PFS benefit was observed in most patient subgroups. Fovinaciclib was also favored across secondary efficacy end points. OS data were immature, with only 40 events (9.6%). The most common treatment-emergent adverse events were hematologic toxic effects, none of which led to serious adverse events or study drug discontinuation. Incidence of discontinuation due to treatment-emergent adverse events was only 1.4% in both arms (3 of 208 receiving fovinaciclib and 3 of 209 receiving placebo). Longitudinal changes in global health status, function domains, and symptom domains of European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 were similar between the 2 arms.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n In this randomized clinical trial, adding fovinaciclib to first-line aromatase inhibitor conferred significant and clinically meaningful PFS benefit and consistent improvements in other efficacy outcomes, along with manageable safety and unaffected quality of life.<\/jats:p>\n <\/jats:sec>\n \n Trial Registration<\/jats:title>\n \n ClinicalTrials.gov Identifier:\n NCT05439499<\/jats:ext-link>\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamaoncol.2026.1938","type":"journal-article","created":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T20:30:16Z","timestamp":1780345816000},"page":"855","source":"Crossref","is-referenced-by-count":1,"title":["Fovinaciclib for First-Line Therapy of Advanced Breast Cancer"],"prefix":"10.1001","volume":"12","author":[{"given":"Peng","family":"Yuan","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Chinese Academy of Medical Sciences Cancer Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunjiang","family":"Liu","sequence":"additional","affiliation":[{"name":"The Breast Center, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Li","sequence":"additional","affiliation":[{"name":"Oncology Department, The First Bethune Hospital of Jilin University, Changchun, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiping","family":"Li","sequence":"additional","affiliation":[{"name":"Internal Medicine of Breast Tumors, Beijing Cancer Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongsheng","family":"Tong","sequence":"additional","affiliation":[{"name":"Medical Department of Breast Diseases, Tianjin Medical University Cancer Institute & Hospital, Tianjin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Cheng","sequence":"additional","affiliation":[{"name":"Department of Breast Oncology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingjuan","family":"Zhang","sequence":"additional","affiliation":[{"name":"Oncology Department, Weihai Municipal Hospital, Weihai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinlu","family":"Shan","sequence":"additional","affiliation":[{"name":"Medical Oncology, Army Medical Center of PLA, Chongqing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jincai","family":"Zhong","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, The First Affiliated Hospital of Guangxi Medical University, Nanning, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tienan","family":"Yi","sequence":"additional","affiliation":[{"name":"Oncology Department, Xiangyang Central Hospital, Xianyang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Liu","sequence":"additional","affiliation":[{"name":"Breast Medical Oncology, Fujian Cancer Hospital, Fuzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huihui","family":"Li","sequence":"additional","affiliation":[{"name":"Breast Internal Medicine Department, Ward 1, Cancer Hospital of Shandong First Medical University, Jinan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Huang","sequence":"additional","affiliation":[{"name":"Breast Surgery II, Affiliated Cancer Hospital of Guangxi Medical University, Nanning, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinsheng","family":"Wu","sequence":"additional","affiliation":[{"name":"Radiation Oncology, The First Affiliated Hospital of Hainan Medical University, Haikou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sijuan","family":"Ding","sequence":"additional","affiliation":[{"name":"Oncology Department, The Central Hospital of Yongzhou, Yongzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Li","sequence":"additional","affiliation":[{"name":"Oncology Department III, Meizhou People\u2019s Hospital, Meizhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Zong","sequence":"additional","affiliation":[{"name":"Medical Oncology 1, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongyan","family":"Jia","sequence":"additional","affiliation":[{"name":"Breast Department, The First Hospital of Shanxi Medical University, Taiyuan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shusen","family":"Wang","sequence":"additional","affiliation":[{"name":"Internal Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kun","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Breast Oncology, Guangdong Provincial People\u2019s Hospital, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongqiang","family":"Guo","sequence":"additional","affiliation":[{"name":"Breast Lymph Comprehensive Internal Medicine, Henan Cancer Hospital, Zhengzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lixia","family":"Ma","sequence":"additional","affiliation":[{"name":"Oncology Department, Jilin Cancer Hospital, Changchun, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhong","family":"Ouyang","sequence":"additional","affiliation":[{"name":"Breast Surgery, The First Affiliated Hospital of Xiamen University, Xiamen, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongtao","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, The First Affiliated Hospital of Bengbu Medical College, Bengbu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Breast Medicine 1, Cancer Hospital of Dalian University of Technology, Cancer Hospital of China Medical University, Liaoning Cancer Hospital and Institute, Shenyang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Lu","sequence":"additional","affiliation":[{"name":"Oncology Department, The First Affiliated Hospital of Henan Medical University, Xinxiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoran","family":"Yang","sequence":"additional","affiliation":[{"name":"Avanc Pharmaceutical Co Ltd, Jinzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingli","family":"Wang","sequence":"additional","affiliation":[{"name":"Shanghai Fosun Pharmaceutical (Group) Co Ltd, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhui","family":"Peng","sequence":"additional","affiliation":[{"name":"Avanc Pharmaceutical Co Ltd, Jinzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lize","family":"Li","sequence":"additional","affiliation":[{"name":"Avanc Pharmaceutical Co Ltd, Jinzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Binghe","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Chinese Academy of Medical Sciences Cancer Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"FCN-437c-III201 Investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aimei","family":"Jiang","sequence":"additional","affiliation":[{"name":"for the FCN-437c-III201 Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Deng","sequence":"additional","affiliation":[{"name":"for the FCN-437c-III201 Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enxiang","family":"Zhou","sequence":"additional","affiliation":[{"name":"for the FCN-437c-III201 Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fenglin","family":"Zhang","sequence":"additional","affiliation":[{"name":"for the FCN-437c-III201 Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fuguo","family":"Tian","sequence":"additional","affiliation":[{"name":"for the FCN-437c-III201 Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guihua","family":"Wang","sequence":"additional","affiliation":[{"name":"for the FCN-437c-III201 Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guijun","family":"Shu","sequence":"additional","affiliation":[{"name":"for the FCN-437c-III201 Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hu","family":"Liu","sequence":"additional","affiliation":[{"name":"for the FCN-437c-III201 Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Yang","sequence":"additional","affiliation":[{"name":"for the FCN-437c-III201 Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huihua","family":"Xiong","sequence":"additional","affiliation":[{"name":"for the FCN-437c-III201 Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huihui","family":"Li","sequence":"additional","affiliation":[{"name":"for the FCN-437c-III201 Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianhui","family":"Li","sequence":"additional","affiliation":[{"name":"for the FCN-437c-III201 Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jidong","family":"Miao","sequence":"additional","affiliation":[{"name":"for the FCN-437c-III201 Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingfen","family":"Wang","sequence":"additional","affiliation":[{"name":"for the FCN-437c-III201 Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingwei","family":"Xu","sequence":"additional","affiliation":[{"name":"for the FCN-437c-III201 Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Li","sequence":"additional","affiliation":[{"name":"for the FCN-437c-III201 Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke","family":"Zheng","sequence":"additional","affiliation":[{"name":"for the FCN-437c-III201 Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunwei","family":"Shen","sequence":"additional","affiliation":[{"name":"for the FCN-437c-III201 Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lili","family":"Zhang","sequence":"additional","affiliation":[{"name":"for the FCN-437c-III201 Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meili","family":"Sun","sequence":"additional","affiliation":[{"name":"for the FCN-437c-III201 Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mopei","family":"Wang","sequence":"additional","affiliation":[{"name":"for the FCN-437c-III201 Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiuyun","family":"Xiong","sequence":"additional","affiliation":[{"name":"for the FCN-437c-III201 Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ru","family":"Chen","sequence":"additional","affiliation":[{"name":"for the FCN-437c-III201 Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shouman","family":"Wang","sequence":"additional","affiliation":[{"name":"for the FCN-437c-III201 Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shundong","family":"Cang","sequence":"additional","affiliation":[{"name":"for the FCN-437c-III201 Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taolang","family":"Li","sequence":"additional","affiliation":[{"name":"for the FCN-437c-III201 Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiping","family":"Tao","sequence":"additional","affiliation":[{"name":"for the FCN-437c-III201 Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weihong","family":"Zhao","sequence":"additional","affiliation":[{"name":"for the FCN-437c-III201 Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojiang","family":"Tang","sequence":"additional","affiliation":[{"name":"for the FCN-437c-III201 Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyan","family":"Li","sequence":"additional","affiliation":[{"name":"for the FCN-437c-III201 Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinshuai","family":"Wang","sequence":"additional","affiliation":[{"name":"for the FCN-437c-III201 Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiuli","family":"Yang","sequence":"additional","affiliation":[{"name":"for the FCN-437c-III201 Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuesong","family":"Li","sequence":"additional","affiliation":[{"name":"for the FCN-437c-III201 Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xujuan","family":"Wang","sequence":"additional","affiliation":[{"name":"for the FCN-437c-III201 Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuli","family":"Meng","sequence":"additional","affiliation":[{"name":"for the FCN-437c-III201 Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yahua","family":"Zhong","sequence":"additional","affiliation":[{"name":"for the FCN-437c-III201 Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Ge","sequence":"additional","affiliation":[{"name":"for the FCN-437c-III201 Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Lu","sequence":"additional","affiliation":[{"name":"for the FCN-437c-III201 Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingying","family":"Du","sequence":"additional","affiliation":[{"name":"for the FCN-437c-III201 Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongmei","family":"Yin","sequence":"additional","affiliation":[{"name":"for the FCN-437c-III201 Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youhuai","family":"Li","sequence":"additional","affiliation":[{"name":"for the FCN-437c-III201 Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Sheng","sequence":"additional","affiliation":[{"name":"for the FCN-437c-III201 Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue\u2019e","family":"Teng","sequence":"additional","affiliation":[{"name":"for the FCN-437c-III201 Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yueyin","family":"Pan","sequence":"additional","affiliation":[{"name":"for the FCN-437c-III201 Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"8","key":"coi260028r1","first-page":"688","article-title":"The natural history of hormone receptor-positive breast cancer.","volume":"26","author":"Lim","year":"2012","journal-title":"Oncology (Williston Park)"},{"issue":"20","key":"coi260028r2","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1056\/NEJMoa1607303","article-title":"Palbociclib and letrozole in advanced breast cancer.","volume":"375","author":"Finn","year":"2016","journal-title":"N Engl J Med"},{"issue":"175","key":"coi260028r3","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/j.ejca.2022.08.012","article-title":"Palbociclib plus letrozole versus placebo plus letrozole in Asian postmenopausal women with oestrogen receptor-positive\/human epidermal growth factor receptor 2-negative advanced breast cancer: primary results from PALOMA-4.","volume":"175","author":"Xu","year":"2022","journal-title":"Eur J Cancer"},{"issue":"32","key":"coi260028r4","doi-asserted-by":"publisher","first-page":"3638","DOI":"10.1200\/JCO.2017.75.6155","article-title":"MONARCH 3: abemaciclib as initial therapy for advanced breast cancer.","volume":"35","author":"Goetz","year":"2017","journal-title":"J Clin Oncol"},{"key":"coi260028r5","doi-asserted-by":"publisher","DOI":"10.1177\/1758835920963925","article-title":"MONARCH plus: abemaciclib plus endocrine therapy in women with HR+\/HER2- advanced breast cancer: the multinational randomized phase III study.","volume":"12","author":"Zhang","year":"2020","journal-title":"Ther Adv Med Oncol"},{"issue":"18","key":"coi260028r6","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.1056\/NEJMoa1609709","article-title":"Ribociclib as first-line therapy for HR-positive, advanced breast cancer.","volume":"375","author":"Hortobagyi","year":"2016","journal-title":"N Engl J Med"},{"issue":"24","key":"coi260028r7","doi-asserted-by":"publisher","first-page":"2465","DOI":"10.1200\/JCO.2018.78.9909","article-title":"Phase III randomized study of ribociclib and fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: MONALEESA-3.","volume":"36","author":"Slamon","year":"2018","journal-title":"J Clin Oncol"},{"issue":"7","key":"coi260028r8","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1016\/S1470-2045(18)30292-4","article-title":"Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial.","volume":"19","author":"Tripathy","year":"2018","journal-title":"Lancet Oncol"},{"issue":"15","key":"coi260028r9","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.7408","article-title":"Initial ribociclib plus endocrine therapy for HR+\/HER2- advanced breast cancer in pre- and postmenopausal Chinese women: primary results from a phase 2 randomized study.","volume":"13","author":"Shao","year":"2024","journal-title":"Cancer Med"},{"issue":"6","key":"coi260028r10","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/S1470-2045(23)00172-9","article-title":"Dalpiciclib plus letrozole or anastrozole versus placebo plus letrozole or anastrozole as first-line treatment in patients with hormone receptor-positive, HER2-negative advanced breast cancer (DAWNA-2): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.","volume":"24","author":"Zhang","year":"2023","journal-title":"Lancet Oncol"},{"issue":"16","key":"coi260028r11","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1200\/JCO.2024.42.16_suppl.1052","article-title":"LEONARDA-2: lerociclib plus letrozole versus placebo plus letrozole in HR+\/HER2- advanced or metastatic breast cancer.","volume":"42","author":"Hu","year":"2024","journal-title":"J Clin Oncol"},{"issue":"12","key":"coi260028r12","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1097\/CM9.0000000000003151","article-title":"Abemaciclib plus non-steroidal aromatase inhibitor or fulvestrant in women with HR+\/HER2- advanced breast cancer: final results of the randomized phase III MONARCH plus trial.","volume":"138","author":"Hu","year":"2025","journal-title":"Chin Med J (Engl)"},{"issue":"13","key":"coi260028r13","doi-asserted-by":"publisher","first-page":"4425","DOI":"10.1158\/1538-7445.AM2019-4425","article-title":"Abstract 4425: FCN-437: a novel, potent and selective oral inhibitor of CDK4\/6 for the treatment of solid tumors.","volume":"79","author":"Lin","year":"2019","journal-title":"Cancer Res"},{"issue":"6","key":"coi260028r14","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1007\/s10637-021-01133-2","article-title":"Phase 1a study of the CDK4\/6 inhibitor, FCN-437c, in Chinese patients with HR?+?\/HER2- advanced breast cancer.","volume":"39","author":"Zhang","year":"2021","journal-title":"Invest New Drugs"},{"issue":"16","key":"coi260028r15","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.16_suppl.e13025","article-title":"The CDK4\/6 inhibitor FCN-437c plus letrozole for the treatment of HR+\/HER2\u2013 advanced breast cancer: updated results from a phase 1b study.","volume":"40","author":"Zhang","year":"2022","journal-title":"J Clin Oncol"},{"issue":"5","key":"coi260028r16","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.SABCS22-P4-01-21","article-title":"Abstract P4-01-21: phase 2 study of the CDK4\/6 inhibitor FCN-437c in combination with fulvestrant or letrozole and goserelin in patients with HR+, HER2\u2013 advanced breast cancer.","volume":"83","author":"Shi","year":"2023","journal-title":"Cancer Res"},{"issue":"10","key":"coi260028r18","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1056\/NEJMoa2114663","article-title":"Overall survival with ribociclib plus letrozole in advanced breast cancer.","volume":"386","author":"Hortobagyi","year":"2022","journal-title":"N Engl J Med"},{"key":"coi260028r17","unstructured":"European Organisation for Research and Treatment of Cancer. EORTC QLQ-C30 Scoring Manual. Accessed December 25, 2025. https:\/\/www.eortc.org\/app\/uploads\/sites\/2\/2018\/02\/SCmanual.pdf"}],"container-title":["JAMA Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/articlepdf\/2849872\/jamaoncology_yuan_2026_oi_260028_1787161683.0969.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T15:02:09Z","timestamp":1787238129000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/fullarticle\/2849872"}},"subtitle":["A Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2026,8,1]]},"references-count":18,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaoncol.2026.1938","relation":{},"ISSN":["2374-2437"],"issn-type":[{"value":"2374-2437","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8,1]]}}}